Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 88

Related Citations for PubMed (Select 18585821)

1.

Immunohistochemical analysis of phosphorylated epidermal growth factor receptor might provide a surrogate marker of EGFR mutation.

Endoh H, Ishibashi Y, Yamaki E, Yoshida T, Yajima T, Kimura H, Kosaka T, Onozato R, Tanaka S, Mitsudomi T, Kuwano H.

Lung Cancer. 2009 Feb;63(2):241-6. doi: 10.1016/j.lungcan.2008.05.013. Epub 2008 Jun 27.

PMID:
18585821
2.

Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.

Schneider CP, Heigener D, Schott-von-Römer K, Gütz S, Laack E, Digel W, Guschall WR, Franke A, Bodenstein H, Schmidtgen C, Reck M.

J Thorac Oncol. 2008 Dec;3(12):1446-53. doi: 10.1097/JTO.0b013e31818ddcaa.

PMID:
19057271
3.

Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients.

Chang JW, Liu HP, Hsieh MH, Fang YF, Hsieh MS, Hsieh JJ, Chiu YT, Tsai HY, Chen YH, Chen YT, Hsu HY, Chen YT, Tsai SF, Chen YR, Hsi BL, Huang SF.

Lung Cancer. 2008 Sep;61(3):328-39. doi: 10.1016/j.lungcan.2008.01.009. Epub 2008 Mar 4.

PMID:
18304690
4.

E-cadherin expression and epidermal growth factor receptor mutation status predict outcome in non-small cell lung cancer patients treated with gefitinib.

Miyanaga A, Gemma A, Ando M, Kosaihira S, Noro R, Minegishi Y, Kataoka K, Nara M, Okano T, Miyazawa H, Tanaka T, Yoshimura A, Kobayashi K, Iwanami H, Hagiwara K, Tsuboi E, Kudoh S.

Oncol Rep. 2008 Feb;19(2):377-83.

PMID:
18202784
5.

Association of the expression of mutant epidermal growth factor receptor protein as determined with mutation-specific antibodies in non-small cell lung cancer with progression-free survival after gefitinib treatment.

Azuma K, Okamoto I, Kawahara A, Taira T, Nakashima K, Hattori S, Kinoshita T, Takeda M, Nakagawa K, Takamori S, Kuwano M, Ono M, Kage M.

J Thorac Oncol. 2012 Jan;7(1):122-7. doi: 10.1097/JTO.0b013e31822eeba2.

PMID:
21892099
6.

Epidermal growth factor receptor (EGFR) mutation and p-EGFR expression in resected non-small cell lung cancer.

McMillen E, Ye F, Li G, Wu Y, Yin G, Liu W.

Exp Lung Res. 2010 Nov;36(9):531-7. doi: 10.3109/01902148.2010.482176.

PMID:
20939760
7.

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA Jr, Varella-Garcia M.

J Natl Cancer Inst. 2005 May 4;97(9):643-55.

8.

Clinico-pathological and biological significance of tyrosine kinase domain gene mutations and overexpression of epidermal growth factor receptor for lung adenocarcinoma.

Ohtsuka K, Ohnishi H, Furuyashiki G, Nogami H, Koshiishi Y, Ooide A, Matsushima S, Watanabe T, Goya T.

J Thorac Oncol. 2006 Oct;1(8):787-95.

PMID:
17409961
9.

Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer.

Zhou Q, Zhang XC, Chen ZH, Yin XL, Yang JJ, Xu CR, Yan HH, Chen HJ, Su J, Zhong WZ, Yang XN, An SJ, Wang BC, Huang YS, Wang Z, Wu YL.

J Clin Oncol. 2011 Aug 20;29(24):3316-21. doi: 10.1200/JCO.2010.33.3757. Epub 2011 Jul 25.

10.

Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancer.

Kitamura A, Hosoda W, Sasaki E, Mitsudomi T, Yatabe Y.

Clin Cancer Res. 2010 Jul 1;16(13):3349-55. doi: 10.1158/1078-0432.CCR-10-0129. Epub 2010 Jun 22.

11.

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).

Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS.

J Clin Oncol. 2011 Jul 20;29(21):2866-74. doi: 10.1200/JCO.2010.33.4235. Epub 2011 Jun 13.

12.

Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI.

Uramoto H, Yamada T, Yano S, Kondo N, Hasegawa S, Tanaka F.

Anticancer Res. 2012 Sep;32(9):3785-90.

PMID:
22993320
13.

Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.

D'Angelo SP, Janjigian YY, Ahye N, Riely GJ, Chaft JE, Sima CS, Shen R, Zheng J, Dycoco J, Kris MG, Zakowski MF, Ladanyi M, Rusch V, Azzoli CG.

J Thorac Oncol. 2012 Dec;7(12):1815-22. doi: 10.1097/JTO.0b013e31826bb7b2.

PMID:
23154553
14.

Phosphorylation status of epidermal growth factor receptor is closely associated with responsiveness to gefitinib in pulmonary adenocarcinoma.

Hijiya N, Miyawaki M, Kawahara K, Akamine S, Tsuji K, Kadota J, Akizuki S, Uchida T, Matsuura K, Tsukamoto Y, Moriyama M.

Hum Pathol. 2008 Mar;39(3):316-23. doi: 10.1016/j.humpath.2007.10.027.

PMID:
18261621
15.

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.

Han SW, Kim TY, Hwang PG, Jeong S, Kim J, Choi IS, Oh DY, Kim JH, Kim DW, Chung DH, Im SA, Kim YT, Lee JS, Heo DS, Bang YJ, Kim NK.

J Clin Oncol. 2005 Apr 10;23(11):2493-501. Epub 2005 Feb 14.

16.

Combined analysis of molecular and clinical predictors of gefitinib activity in advanced non-small cell lung cancer: epidermal growth factor receptor mutations do not tell the whole story.

Argiris A, Hensing T, Yeldandi A, Patel S, Raji A, Sturgis C, Masters G, Gooding W, Pins M, Kolesar J.

J Thorac Oncol. 2006 Jan;1(1):52-60.

PMID:
17409827
17.

Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).

Cadranel J, Mauguen A, Faller M, Zalcman G, Buisine MP, Westeel V, Longchampt E, Wislez M, Coudert B, Daniel C, Chetaille B, Michiels S, Blons H, Solassol J, De Fraipont F, Foucher P, Urban T, Lacroix L, Poulot V, Quoix E, Antoine M, Danton G, Morin F, Chouaid C, Pignon JP.

J Thorac Oncol. 2012 Oct;7(10):1490-502.

PMID:
22982650
18.

Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors.

Chang MH, Ahn HK, Lee J, Jung CK, Choi YL, Park YH, Ahn JS, Park K, Ahn MJ.

Cancer. 2011 Jan 1;117(1):143-51. doi: 10.1002/cncr.25560. Epub 2010 Aug 27.

19.

Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.

Ludovini V, Bianconi F, Pistola L, Chiari R, Minotti V, Colella R, Giuffrida D, Tofanetti FR, Siggillino A, Flacco A, Baldelli E, Iacono D, Mameli MG, Cavaliere A, Crinò L.

J Thorac Oncol. 2011 Apr;6(4):707-15. doi: 10.1097/JTO.0b013e31820a3a6b.

PMID:
21258250
20.

Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.

Takeda M, Okamoto I, Tsurutani J, Oiso N, Kawada A, Nakagawa K.

Jpn J Clin Oncol. 2012 Jun;42(6):528-33. doi: 10.1093/jjco/hys042. Epub 2012 Mar 28.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk